Table 4.
Progression‐free survival and overall survival in patients treated with urelumab or urelumab plus rituximab
| DLBCL | FL | Other B‐cell lymphomas | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Urelumab | Urelumab Plus Rituximab | Urelumab | Urelumab Plus Rituximab | Urelumab | ||||||||||||||||
| 8 mg Q3W (n = 10) | 8 mg Q6W (n = 18) | 0.3 mg/kg (n = 3) | Total (N = 31) | 0.1 mg/kg (n = 14) | 8 mg Q3W (n = 12) | 0.3 mg/kg (n = 3) | Total (N = 29) | 8 mg Q3W (n = 10) | 8 mg Q6W (n = 2) | 0.3 mg/kg (n = 5) | Total (N = 17) | 0.1 mg/kg (n = 3) | 8 mg Q3W (n = 11) | 0.3 mg/kg (n = 3) | Total (N = 17) | 8 mg Q3W (n = 5) | 8 mg Q6W (n = 5) | 0.3 mg/kg (n = 2) | Total (N = 12) | |
| PFS | ||||||||||||||||||||
| Events, n (%) | 8 (80) | 13 (72) | 3 (100) | 24 (77) | 13 (93) | 11 (92) | 3 (100) | 27 (93) | 10 (100) | 1 (50) | 2 (40) | 13 (76) | 2 (67) | 4 (36) | 1 (33) | 7 (41) | 5 (100) | 3 (60) | 1 (50) | 9 (75) |
| Median (95% CI), weeks | 8.1 (2.9‐17.0) | 8.0 (3.1‐8.4) | 24.6 (9.1‐30.4) | 8.1 (5.3‐9.1) | 11.6 (4.4‐12.3) | 7.4 (3.0‐12.3) | 12.4 (6.6‐25.3) | 9.0 (5.6‐12.3) | 8.2 (5.1‐9.3) | NR (8.3 to −) | NR (7.0 to −) | 8.9 (6.4‐15.0) | 40.4 (30.3 to −) | 35.1 (2.3 to −) | NR (3.7 to −) | 40.4 (12.1 to −) | 8.4 (1.7‐26.3) | 15.4 (4.1 to −) | NR (22.4 to −) | 13.4 (2.4‐26.3) |
| OS | ||||||||||||||||||||
| Events, n (%) | 4 (40) | 7 (39) | 1 (33) | 12 (39) | 7 (50) | 8 (67) | 1 (33) | 16 (55) | 2 (20) | 0 | 0 | 2 (12) | 0 | 1 (9) | 1 (33) | 2 (12) | 2 (40) | 1 (20) | 0 | 3 (25) |
| Median (95% CI), weeks | 31.1 (2.9 to −) | 30.7 (21.7 to −) | NR (45.6 to −) | 45.6 (28.9 to −) | 45.7 (15.6‐98.0) | 19.6 (10.0 to −) | NR (13.3 to −) | 23.9 (18.1‐98.0) | 64.3 (28.7‐64.3) | − | − | NR (28.7 to −) | − | NR (10.6 to −) | NR (3.7 to −) | NR | 42.6 (2.4 to −) | NR (19.6 to −) | − | NR (19.6 to −) |
Abbreviations: DLBCL, diffuse large B‐cell lymphoma; FL, follicular lymphoma; NR, not reached; OS, overall survival; PFS, progression‐free survival.